Colorado-based biotechnology company leveraging AI to develop new medicines from naturally available materials, Enveda Biosciences, has raised $130 million in Series C funding round spearheaded by FVP and Kinnevik. New and existing investors, including Premji Invest, Baillie Gifford, Lingotto Innovation, Dimension Capital, Lux Capital, True Ventures, The Nature Conservancy, Henry R. Kravis, and Cresset Partners, supported the investment round, which boosted the company’s total funding to $360 million.